Why is Orchid Pharma falling/rising?

As of 06-Nov, Orchid Pharma Ltd's stock price is currently at 816.00, reflecting an increase of 26.7, or 3.38%. The stock has been on an upward trend, gaining for the last four consecutive days and achieving a return of 15.06% over the past week, outperforming the sector by 4.15%. Despite this recent positive momentum, the company has faced significant challenges, including a weak long-term fundamental strength characterized by a low average Return on Equity (ROE) of 4.68% and a concerning EBIT to Interest ratio of 1.99. Additionally, the company has reported negative results for the last three consecutive quarters, with a notable decline in operating profit of -19.64% and a year-over-year profit decrease of -23.6%, which may temper investor enthusiasm despite the recent price increase.
In the broader market context, Orchid Pharma's short-term performance stands in stark contrast to the benchmark, as the Sensex has experienced a decline of 1.30% over the past week. While Orchid's recent gains are notable, its year-to-date performance remains poor, with a decline of -55.09% compared to the Sensex's increase of 6.62%. This underperformance over the longer term, coupled with the company's ongoing financial struggles, suggests that while there may be short-term gains, the overall outlook remains cautious as investors weigh the stock's potential against its fundamental weaknesses.